Related Experiment Video
Updated: Jul 17, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
[Cardiovascular pharmaceuticals: a risk while driving vehicles]
Ana Rosa Alconero Camarero1, Ana Sangrador Rasero, María Casaus Pérez
1EUE Casade Salud Valdecilla, Universidad de Cantabria. alconear@unican.es
Objective:
To categorize cardiovascular pharmaceuticals according to their respective effect on one's capacity to drive a vehicle.
Methodology:
an analysis of the technical file for 299 pharmaceutical products belonging to 1 lsubgroups inside the main category of therapeutic products related to the cardiovascular apparatus. Information compiled includes: the existence, or lack of, a section which warns of the possible effects of the medication on a person's capacity to drive a vehicle; in those affirmative cases, a statement specifying those effects.
Conclusions:
32.1% of pharmaceutical products do not comply with the existing legislation and approximately half of those pharmaceutical products do not have a section on their effects on a person's capacity to drive a vehicle, or they state these products have an effect but do not bear an influence even though they can provoke important effects.
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drug Toxicity: Risk factors
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Antihypertensive Drugs: Vasodilators
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
